% 0期刊文章%一个亚当Strzelczyk % Susanne Knake % Reetta Kalviainen %一个Estevo Santamarina %曼努埃尔·托莱多%一个索菲亚Willig %亚历山德拉Rohracher %尤金Trinka % Felix罗斯诺夫% T Perampanel用于建立,耐火材料,和Super-Refractory癫痫持续状态(SE):总结病例从奥地利、芬兰、德国和西班牙(p3.5 - 005) % D J神经病学2019% % P p3.5 - 005 V % N % 15补充X 92%目的:总结病例Perampanel用于建立,耐火材料,和Super-Refractory SE (SRSE)。首页背景:小说需要治疗来控制难治性SE。Perampanel不是目前SE许可;有有限的临床数据评估perampanel SE治疗的有效性,为指导治疗策略案例报告是有价值的。设计/方法:病历回顾性综述perampanel管理SE在欧洲五医院接受治疗患者在2011 - 2015之间。病例分类根据2015年国际抗癫痫联盟的定义。临床特点、治疗参数、治疗结果和安全结果包含在数据收集中。结果:总体而言,3.9%(52/1319)的患者经历SE收到perampanel。平均延迟从SE出现perampanel起始是10天。perampanel之前,苯二氮卓类未能在所有患者接受他们(n = 51/51);病人没有平均五个其他抗癫痫药物(aed)。初始perampanel剂量中位数为6毫克/天; median maximum perampanel dose was 10 mg/day. Perampanel was the last drug added in 32/52 (61.5%) patients, with response attributed to perampanel in 19/52 (36.5%) patients. A greater proportion of perampanel non-responders had SRSE (51.5% [n=17/33]) vs perampanel responders (31.6% [n=6/19]) and failed a higher mean number of AEDs before initiating perampanel (5.9 vs 5.1, respectively). Most commonly reported adverse effects (AEs) during perampanel treatment were dizziness (n=1 [1.9%]) and somnolence (n=1 [1.9%]). No serious AEs or AEs leading to perampanel discontinuation were documented.Conclusions: Across the SE cases reported here, perampanel was administered at greater initial doses than what is routinely administered to patients with epilepsy. The rate of seizure cessation attributed to perampanel treatment (36.5%) in this refractory and heterogeneous population represents a notable response. These data should be confirmed in a larger patient population.Funding: Medical writing support, under the direction of the authors, was funded by Eisai Inc.Disclosure: Dr. Strzelczyk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Desitin, UCB Pharma, Zogenix. Dr. Strzelczyk has received research support from UCB Pharma, Zogenix. Dr. Knake has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB Pharma. Dr. Knake has received research support from AD-Tech, Bial, Brainlab, Desitin, Eisiai, GE Pharma, Siemens, and UCB Pharma. Dr. Kälviäinen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Orion, GW Pharma, Takeda and UCB Pharma. Dr. Santamarina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, UCB, and Esteve. Dr. Santamarina has received research support from UCB. Dr. Toledo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bial, Eisai, Esteve, Novartis, Shire and UCB. Dr. Toledo has received research support from Bial, Eisai, and UCB Pharma. Dr. Willig has nothing to disclose. Dr. Rohracher has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai. Dr. Trinka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Biogen, Ever, Peuropharm, Medtronics, Bial, UCB, GL Pharma, GlaxoSmithKline, Boehringer, Sunovion, Actavis. Dr. Trinka has received research support from Biogen, UCB, Red Bull, Merck and Eisai. Dr. Rosenow has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Medtronic, UCB Pharma, GW Pharma, and Neurokonsil. Dr. Rosenow has received research support from UCB Pharma. %U